SCHEMBL30700995

SCHEMBL30700995

O=C1NCc2c1ccnc2-c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.50
PARP10 Q53GL7 3/20 0.44
PARP11 Q9NR21 3/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
BRAF P15056 2/20 0.42
CDK5 Q00535 3/20 0.41
DYRK1A Q13627 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
CSNK1A1 P48729 2/20 0.41
ROCK1 Q13464 2/20 0.41
LRRK2 Q5S007 2/20 0.41
DYRK1B Q9Y463 2/20 0.41
PIM1 P11309 1/20 0.41
LTK P29376 1/20 0.40
MST1R Q04912 1/20 0.40
MAPKAPK2 P49137 2/20 0.39
CDK9 P50750 2/20 0.38
PLK4 O00444 1/20 0.38
MAPK13 O15264 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14352065 0.87 CDC7 (0.46) CDC7PARP10PARP11PDE3BPDE3A
SCHEMBL30700820 0.80 CDK5 (0.38) CDC7PARP10PARP11BRAFCDK5
SCHEMBL18789132 0.78 PRKCI (0.56) BRAFCLK4ROCK1DYRK1BPIM1
SCHEMBL30543363 0.78 GSTP1 (0.43) CDK5DYRK1ACLK4CSNK1A1ROCK1
SCHEMBL29845432 0.76 CLK4 (0.57) CDC7PARP10PARP11CDK5DYRK1A
SCHEMBL30775203 0.73 PARP10 (0.45) PARP10PARP11PDE3BPDE3ACDK5
SCHEMBL30461697 0.72 CDC7 (0.49) CDC7PARP10PARP11PDE3BPDE3A
SCHEMBL30775316 0.72 PARP10 (0.46) PARP10PARP11PIM1MAPKAPK2MAPK1
SCHEMBL24466337 0.72 CDK5 (0.46) PARP10PARP11CDK5DYRK1ACLK4
SCHEMBL31264207 0.72 CDK5 (0.46) CDK5DYRK1ACLK4CSNK1A1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
CN-117295737-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2023-12-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CDC7 2497/4885PARP10 2840/4885PARP11 2862/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CDC7 2497/4885PARP10 2840/4885PARP11 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.